Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Total Liabilities (2023 - 2026)

Prelude Therapeutics' Total Liabilities history spans 4 years, with the latest figure at $59.5 million for Q1 2026.

  • On a quarterly basis, Total Liabilities rose 56.13% to $59.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $59.5 million, a 56.13% increase, with the full-year FY2025 number at $72.7 million, up 64.97% from a year prior.
  • Total Liabilities hit $59.5 million in Q1 2026 for Prelude Therapeutics, down from $72.7 million in the prior quarter.
  • Over the last five years, Total Liabilities for PRLD hit a ceiling of $72.7 million in Q4 2025 and a floor of $36.2 million in Q3 2025.
  • Historically, Total Liabilities has averaged $44.9 million across 4 years, with a median of $40.7 million in 2023.
  • The widest YoY moves for Total Liabilities: up 64.97% in 2025, down 11.2% in 2025.
  • Tracing PRLD's Total Liabilities over 4 years: stood at $40.6 million in 2023, then grew by 8.58% to $44.1 million in 2024, then surged by 64.97% to $72.7 million in 2025, then dropped by 18.19% to $59.5 million in 2026.
  • Business Quant data shows Total Liabilities for PRLD at $59.5 million in Q1 2026, $72.7 million in Q4 2025, and $36.2 million in Q3 2025.